Matricelf Ltd (TASE: MTLF)
Health Care · Biotechnology · IL
₪2.71
+4.12% today · +30.5% 1Y
Matricelf Ltd (TASE: MTLF) operates in the Biotechnology industry within the Health Care sector. The company is valued at $26.77M and employs 15 people.
Over the last twelve months the share price has gained 30.5%, trading between 2.07 and 8.53.
Tweenvest scores Matricelf Ltd across four factors: quality 25/100. Its strongest factor is quality.
MTLF price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $26.77M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.51
- Dividend yield
- —
- Beta (5Y)
- 0.32
- 52-week high
- ₪8.53
- 52-week low
- ₪2.07
- Avg volume (3M)
- —
- Shares outstanding
- 29.24M
- Employees
- 15
- Next earnings
- —
About Matricelf Ltd
Matricelf Ltd, a biotechnology company, develops a platform for autologous tissue engineering for various medical conditions. The company’s regenerative medicine platform intends to cure a range of medical conditions, including spinal cord injuries, age-related macular degeneration, Parkinson’s disease, and myocardial infarction, as well as for 3D bioprinting. The company has a strategic collaboration with Sheba Medical Center for the development and clinical advancement of its neural tissue implant product for the treatment of spinal cord injury. The company has a strategic collaboration with CiRA Foundation for the development of regenerative manufacturing technologies and the evaluation of iPSC-based neural tissue engineering for therapeutic applications. The company was incorporated in 2019 and is based in Ness Ziona, Israel.
- ISIN
- IL0011767915
- Founded
- 2019
- Listed since
- Jun 21, 2021
- Exchange
- The Tel-Aviv Stock Exchange
- Currency
- ILS
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $266.00 | +0.08% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.45 | +0.05% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.